Selective progesterone receptor modulators and reproductive health
review
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Selective progesterone receptor modulators (SPRMs) like mifepristone and ulipristal acetate show promise for reproductive health but require further study due to potential liver function abnormalities with chronic use.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
PURPOSE OF REVIEW: This review is intended to provide perspective on the history of selective progesterone receptor modulators (SPRMs) and progesterone antagonists, their current availability, therapeutic promise and safety concerns.
RECENT FINDINGS: Despite keen interest in synthesis of these compounds, only a handful have had clinical test results allowing for commercialization. Mifepristone is well tolerated and effective for single dose first trimester at-home pregnancy termination and is available in much of the world. Ulipristal acetate, at single doses, is well tolerated and effective for emergency contraception, with less availability. Chronic use of these agents has been associated with abnormal liver enzymes, and rarely, with hepatic failure; causality is not understood.
SUMMARY: SPRMs and progesterone antagonists have great therapeutic promise for use in other reproductive disorders, including breast cancer, endometriosis, adenomyosis, estrogen-free contraception and cervical ripening but require additional study. Alternative formulations, whether local (topical breast or intrauterine) or extended-release may reduce the incidence of liver function abnormalities and should be explored.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator 2009
- Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy 2003
- Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies 2018
Cited by (1)
References (44)
- Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy via openalex
- Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies via openalex
- Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator via openalex
- W1985213624 via openalex
- W2001099922 via openalex
- W2002357201 via openalex
- W2016301974 via openalex
- W2022797066 via openalex
- W2026392453 via openalex
- W2041145382 via openalex
- W2083535001 via openalex
- W2097851570 via openalex
- W2108256325 via openalex
- W2128954873 via openalex
- W2142037633 via openalex
- W2153804622 via openalex
- W2155916082 via openalex
- W2167223040 via openalex
- W2247087212 via openalex
- W2319602870 via openalex
- W2332516206 via openalex
- W2922487559 via openalex
- W2984199235 via openalex
- W2989317082 via openalex
- W2989564553 via openalex
- W3022558870 via openalex
- W3081386294 via openalex
- W3090399818 via openalex
- W3132047785 via openalex
- W3139979424 via openalex
- W3145146375 via openalex
- W3159923152 via openalex
- W3199927457 via openalex
- W4211227828 via openalex
- W4238445171 via openalex
- W6638165750 via openalex
- W6639007481 via openalex
- W6660723231 via openalex
- W6700011400 via openalex
- W6790985241 via openalex
- W1802161029 via openalex
- W7073993271 via openalex
- W1983768667 via openalex
- W1984592479 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-08-26T06:08:41.316361+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-07-14T06:08:25.154024+00:00
- unpaywall
- last seen: 2026-08-26T06:23:03.089193+00:00
License: CC0
· commercial use OK